ロード中...
Targeting immune-checkpoint inhibitor resistance mechanisms by MEK inhibitor and agonist anti-CD40 antibody combination therapy
The widespread application of immune-checkpoint blockade (ICB) has resulted in unprecedented response rates in patients with immunogenic cancers, such as melanoma and lung cancer. However, sub-groups of patients with these indications do not respond to ICB, and the same applies to patients with othe...
保存先:
| 出版年: | Cell Stress |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Shared Science Publishers OG
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7520667/ https://ncbi.nlm.nih.gov/pubmed/33024933 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15698/cst2020.10.233 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|